Experimental gene therapy for sensorineural hearing loss is currently transitioning from preclinical research to initial human trials in Israel. While scientists develop advanced adeno-associated virus vectors, these treatments are not yet standard. Stem-cell therapies remain in early laboratory stages and are not widely available.
- Regulatory oversight: Israel Genetic Information Law requires advisory committee approval for all cellular modifications.
- Targeted mutations: Research specifically focuses on the CLIC5 gene to preserve inner-ear hair cells.
- Access protocol: Patients typically access experimental options through controlled clinical trials at university hospitals.
- Standard alternative: Cochlear implant placement remains the primary established treatment for profound hearing loss.
Bookimed Expert Insight: While Israel is a research leader, clinical reality lags behind laboratory breakthroughs. Specialists like Dr. Ophir Hendzel at Sourasky Medical Center focus on cochlear implants which are the reliable standard. Patients should prioritize clinics with heavy research volume like Hadassah, which handles 1,000,000 patients annually.
Patient Consensus: Patients note that while the future of gene therapy is promising, cochlear implants are the only current practical solution. Many emphasize checking official trial registries regularly rather than seeking unapproved private stem-cell clinics.
